PL2696878T3 - Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej - Google Patents

Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej

Info

Publication number
PL2696878T3
PL2696878T3 PL12717824T PL12717824T PL2696878T3 PL 2696878 T3 PL2696878 T3 PL 2696878T3 PL 12717824 T PL12717824 T PL 12717824T PL 12717824 T PL12717824 T PL 12717824T PL 2696878 T3 PL2696878 T3 PL 2696878T3
Authority
PL
Poland
Prior art keywords
sapacitabine
decitabine
combination
myeloid leukemia
acute myeloid
Prior art date
Application number
PL12717824T
Other languages
English (en)
Polish (pl)
Inventor
Judy Chiao
Original Assignee
Cyclacel Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1106339.3A external-priority patent/GB201106339D0/en
Priority claimed from GBGB1117693.0A external-priority patent/GB201117693D0/en
Priority claimed from GBGB1121105.9A external-priority patent/GB201121105D0/en
Application filed by Cyclacel Limited filed Critical Cyclacel Limited
Publication of PL2696878T3 publication Critical patent/PL2696878T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL12717824T 2011-04-14 2012-04-13 Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej PL2696878T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1106339.3A GB201106339D0 (en) 2011-04-14 2011-04-14 Combination
GBGB1117693.0A GB201117693D0 (en) 2011-10-13 2011-10-13 Combination
GBGB1121105.9A GB201121105D0 (en) 2011-12-08 2011-12-08 Combination
EP12717824.2A EP2696878B1 (en) 2011-04-14 2012-04-13 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
PCT/GB2012/050815 WO2012140436A1 (en) 2011-04-14 2012-04-13 Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
PL2696878T3 true PL2696878T3 (pl) 2020-01-31

Family

ID=46022492

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12717824T PL2696878T3 (pl) 2011-04-14 2012-04-13 Schemat dawkowania dla sapacytabiny i decytabiny w kombinacji do leczenia ostrej białaczki szpikowej

Country Status (7)

Country Link
US (2) US10226478B2 (enExample)
EP (2) EP2696878B1 (enExample)
JP (1) JP6093755B2 (enExample)
ES (1) ES2743691T3 (enExample)
HU (1) HUE046177T2 (enExample)
PL (1) PL2696878T3 (enExample)
WO (1) WO2012140436A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2696878B1 (en) 2011-04-14 2019-07-10 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia
EP2874631A1 (en) 2012-05-15 2015-05-27 Cyclacel Limited Dosage regimen for sapacitabine and seliciclib
EP3074018A1 (en) 2013-11-27 2016-10-05 Oncoethix GmbH Method of treating leukemia using pharmaceutical formulation containing thienotriazolodiazepine compounds
WO2019081951A1 (en) 2017-10-27 2019-05-02 Cyclacel Limited DOSAGE REGIME
WO2021079129A1 (en) 2019-10-24 2021-04-29 Cyclacel Limited Dosing regimen

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2559917B2 (ja) 1990-06-15 1996-12-04 三共株式会社 ピリミジンヌクレオシド誘導体
RU2085557C1 (ru) 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
US5824984A (en) 1997-03-31 1998-10-20 Morrow; John A. Portable electric wire cutter
GB9718913D0 (en) 1997-09-05 1997-11-12 Glaxo Group Ltd Substituted oxindole derivatives
US6403632B1 (en) 2000-03-01 2002-06-11 Bristol Myers Squibb Pharma Co Lactam metalloprotease inhibitors
US6835185B2 (en) 1998-12-21 2004-12-28 Micrus Corporation Intravascular device deployment mechanism incorporating mechanical detachment
US6462063B1 (en) 2000-02-04 2002-10-08 Fibrogen, Inc. C-proteinase inhibitors
US20020156033A1 (en) 2000-03-03 2002-10-24 Bratzler Robert L. Immunostimulatory nucleic acids and cancer medicament combination therapy for the treatment of cancer
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
IL153020A0 (en) 2000-05-26 2003-06-24 Idenix Cayman Ltd Methods and compositions for treating flaviviruses and pestiviruses
DK1296714T3 (da) 2000-06-22 2009-12-07 Coley Pharm Gmbh Kombination af CpG og antistoffer, der er rettet mod CD19, CD20, CD22 eller CD40 til behandling eller forebyggelse af kræft
AU2002230385A1 (en) 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
BR0114837A (pt) 2000-10-18 2006-05-09 Pharmasset Ltd nucleosìdeos modificados para tratamento de infecções viróticas e proliferação celular anormal
AU2002228885A1 (en) 2000-10-18 2002-04-29 Pharmasset Inc Simultaneous quantification of nucleic acids in diseased cells
AU2002228849A1 (en) 2000-12-08 2002-06-18 Bristol-Myers Squibb Pharma Company Semicarbazides and their uses as cyclin dependent kinase inhibitors
JP3748536B2 (ja) 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
US6908906B2 (en) 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
US6837901B2 (en) 2001-04-27 2005-01-04 Intek Technology L.L.C. Methods for delivering, repositioning and/or retrieving self-expanding stents
US6890915B2 (en) 2001-05-25 2005-05-10 Bristol-Myers Squibb Pharma Company Hydantoins and related heterocycles as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
US6949558B2 (en) 2001-11-07 2005-09-27 Yale University Enhancement of taxane-based chemotherapy by a CDK1 antagonist
US7137993B2 (en) 2001-12-03 2006-11-21 Xtent, Inc. Apparatus and methods for delivery of multiple distributed stents
US8383605B2 (en) 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
CA2526212C (en) 2003-05-16 2013-08-27 Hybridon, Inc. Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
US20050014716A1 (en) 2003-05-21 2005-01-20 Wang Jin Wei Pancreatic cancer treatment
GB0328180D0 (en) 2003-12-04 2004-01-07 Cyclacel Ltd Combination
US20090047365A1 (en) 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
US20060212898A1 (en) 2005-03-17 2006-09-21 Ryan Steelberg System and method for broadcast target advertising
GB0523041D0 (en) 2005-11-11 2005-12-21 Cyclacel Ltd Combination
GB0526419D0 (en) 2005-12-23 2006-02-08 Cyclacel Ltd Formulation
GB0609530D0 (en) 2006-05-12 2006-06-21 Cyclacel Ltd Combination
EP2049106A2 (en) 2006-07-14 2009-04-22 Astex Therapeutics Limited Pharmaceutical combinations
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
PL2148676T3 (pl) 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
CN101185629A (zh) 2007-12-14 2008-05-28 山东蓝金生物工程有限公司 一种治疗实体肿瘤的地西他滨缓释剂
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
EP2307002B1 (en) 2008-06-09 2013-01-02 Cyclacel Limited Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
EP2696878B1 (en) 2011-04-14 2019-07-10 Cyclacel Limited Dosage regimen for sapacitabine and decitabine in combination for treating acute myeloid leukemia

Also Published As

Publication number Publication date
EP2696878B1 (en) 2019-07-10
WO2012140436A1 (en) 2012-10-18
JP2014510780A (ja) 2014-05-01
JP6093755B2 (ja) 2017-03-08
US10226478B2 (en) 2019-03-12
US20140094428A1 (en) 2014-04-03
EP3560501A1 (en) 2019-10-30
HUE046177T2 (hu) 2020-02-28
EP2696878A1 (en) 2014-02-19
US20190314396A1 (en) 2019-10-17
ES2743691T3 (es) 2020-02-20

Similar Documents

Publication Publication Date Title
IL274206A (en) MASP-2 suppressors for use in the treatment of radiation heredity syndrome
GB2509271B (en) Patient-specific sacroiliac guides and associated methods
IL236962B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
PL2928431T3 (pl) Wyroby chłonne z kanałami
PL2928430T3 (pl) Wyroby chłonne z kanałami
IL233948B (en) A smoking item that includes dual heat conductive components
GB201313257D0 (en) MALDimaging and ion guide
ZA201507278B (en) Gla monotherapy for use in cancer treatment
IL218108A0 (en) Il1rap expression on acute and chronic myeloid leukemia cells
ZA201401527B (en) Improvements in lockers
PL2780332T3 (pl) Morfolinylobenzotriazyny do zastosowania w terapii rakowej
IL229243A0 (en) Complementary factor b analogs and their uses
ZA201301708B (en) Package with window and unit dose articles therein
EP2621516A4 (en) INTERFERON BETA FOR USE AS MONOTHERAPY OR IN COMBINATION WITH OTHER CANCER THERAPIES
HUE046177T2 (hu) Szapacitabin és decitabin kombinációjának adagolási rendje akut mieloid leukémia kezelésére
IL238453A0 (en) Trans-clomiphene for use in cancer treatment
IL238606B (en) CD44v6-derivative peptides for the treatment of cancer metastases
ZA201306442B (en) Chop gate and nozzle
ZA201406172B (en) Compounds and methods for treating leukemia
GB201311440D0 (en) Improvements in or relating to seat belt assemblies
ZA201402151B (en) Romidepsin and 5- azacitidine for use in treating lymphoma
HUE046993T2 (hu) Készítmény radioterápia és kemoterápia által okozott leukopenia megelõzésében és kezelésében történõ alkalmazásra
PL2769727T3 (pl) Kombinacja deoksynukleozydu/nukleozydu do stosowania w leczeniu nowotworów
HUE047342T2 (hu) Tapentadol a trigeminális neuralgiával kapcsolatos fájdalom kezelése során történõ alkalmazásra
EP2714061A4 (en) AGGREGATE AND TEA TO IMPROVE AUTISM